BACKGROUND: Alcohol use disorders are chronic disabling conditions for which existing pharmacotherapies have only modest efficacy. In the present review, derived from the 2012 Behavior, Biology and Chemistry "Translational Research in Addiction" symposium, we summarize the anti-relapse potential of corticotropin-releasing factor type 1 (CRF(1)) receptor antagonists to reduce negative emotional symptoms of acute and protracted alcohol withdrawal and stress-induced relapse to alcohol seeking. METHODS: We review the biology of CRF(1) systems, the activity of CRF(1) receptor antagonists in animal models of anxiolytic and antidepressant activity, and experimental findings in alcohol addiction models. We also update the clinical trial status of CRF(1) receptor antagonists, including pexacerfont (BMS-562086), emicerfont (GW876008), verucerfont (GSK561679), CP316311, SSR125543A, R121919/NBI30775, R317573/19567470/CRA5626, and ONO-2333Ms. Finally, we discuss the potential heterogeneity and pharmacogenomics of CRF(1) receptor pharmacotherapy for alcohol dependence. RESULTS: The evidence suggests that brain penetrant-CRF(1) receptor antagonists have therapeutic potential for alcohol dependence. Lead compounds with clinically desirable pharmacokinetic properties now exist, and longer receptor residence rates (i.e., slow dissociation) may predict greater CRF(1) receptor antagonist efficacy. Functional variants in genes that encode CRF system molecules, including polymorphisms in Crhr1 (rs110402, rs1876831, rs242938) and Crhbp genes (rs10055255, rs3811939) may promote alcohol seeking and consumption by altering basal or stress-induced CRF system activation. CONCLUSIONS: Ongoing clinical trials with pexacerfont and verucerfont in moderately to highly severe dependent anxious alcoholics may yield insight as to the role of CRF(1) receptor antagonists in a personalized medicine approach to treat drug or alcohol dependence.
BACKGROUND:Alcohol use disorders are chronic disabling conditions for which existing pharmacotherapies have only modest efficacy. In the present review, derived from the 2012 Behavior, Biology and Chemistry "Translational Research in Addiction" symposium, we summarize the anti-relapse potential of corticotropin-releasing factor type 1 (CRF(1)) receptor antagonists to reduce negative emotional symptoms of acute and protracted alcohol withdrawal and stress-induced relapse to alcohol seeking. METHODS: We review the biology of CRF(1) systems, the activity of CRF(1) receptor antagonists in animal models of anxiolytic and antidepressant activity, and experimental findings in alcohol addiction models. We also update the clinical trial status of CRF(1) receptor antagonists, including pexacerfont (BMS-562086), emicerfont (GW876008), verucerfont (GSK561679), CP316311, SSR125543A, R121919/NBI30775, R317573/19567470/CRA5626, and ONO-2333Ms. Finally, we discuss the potential heterogeneity and pharmacogenomics of CRF(1) receptor pharmacotherapy for alcohol dependence. RESULTS: The evidence suggests that brain penetrant-CRF(1) receptor antagonists have therapeutic potential for alcohol dependence. Lead compounds with clinically desirable pharmacokinetic properties now exist, and longer receptor residence rates (i.e., slow dissociation) may predict greater CRF(1) receptor antagonist efficacy. Functional variants in genes that encode CRF system molecules, including polymorphisms in Crhr1 (rs110402, rs1876831, rs242938) and Crhbp genes (rs10055255, rs3811939) may promote alcohol seeking and consumption by altering basal or stress-induced CRF system activation. CONCLUSIONS: Ongoing clinical trials with pexacerfont and verucerfont in moderately to highly severe dependent anxious alcoholics may yield insight as to the role of CRF(1) receptor antagonists in a personalized medicine approach to treat drug or alcohol dependence.
Authors: Y L Chen; R S Mansbach; S M Winter; E Brooks; J Collins; M L Corman; A R Dunaiskis; W S Faraci; R J Gallaschun; A Schmidt; D W Schulz Journal: J Med Chem Date: 1997-05-23 Impact factor: 7.446
Authors: Emily M Jutkiewicz; Susan K Wood; Hani Houshyar; Ling-Wei Hsin; Kenner C Rice; James H Woods Journal: Psychopharmacology (Berl) Date: 2005-02-05 Impact factor: 4.530
Authors: Marisa Roberto; Maureen T Cruz; Nicholas W Gilpin; Valentina Sabino; Paul Schweitzer; Michal Bajo; Pietro Cottone; Samuel G Madamba; David G Stouffer; Eric P Zorrilla; George F Koob; George R Siggins; Loren H Parsons Journal: Biol Psychiatry Date: 2010-01-08 Impact factor: 13.382
Authors: Melanie L Schwandt; Carlos R Cortes; Laura E Kwako; David T George; Reza Momenan; Rajita Sinha; Dimitri E Grigoriadis; Emilio Merlo Pich; Lorenzo Leggio; Markus Heilig Journal: Neuropsychopharmacology Date: 2016-04-25 Impact factor: 7.853
Authors: Melissa A Herman; Florence P Varodayan; Christopher S Oleata; George Luu; Dean Kirson; Markus Heilig; Roberto Ciccocioppo; Marisa Roberto Journal: Neuropharmacology Date: 2015-10-28 Impact factor: 5.250